XML 368 R17.htm IDEA: XBRL DOCUMENT v3.25.0.1
SUPPLEMENTAL CASH FLOW AND OTHER DATA
 12 Months Ended
Dec. 31, 2024
Supplemental Cash Flow Elements [Abstract]  
SUPPLEMENTAL CASH FLOW AND OTHER DATA SUPPLEMENTAL CASH FLOW AND OTHER DATA
    Supplemental cash flow and other data for the years ended December 31, 2024, 2023 and 2022 was as follows:
    
202420232022
Depreciation expense$366 $331 $317 
Amortization expense127 108 120 
Depreciation and amortization expense$493 $439 $437 
Interest expense$(226)$(163)$(148)
Interest income25 11 10 
Interest expense, net$(201)$(152)$(138)
Interest paid$262 $134 $156 
Income taxes paid$256 $317 $283 
Accounts payable associated with capital expenditures$60 $42 $38 
Accounts payable associated with purchases of treasury stock$— $1 $— 
Dividend payable$84 $79 $74 
Dividends received from equity method investees$33 $26 $61 
Businesses acquired:  
Fair value of assets acquired$2,397 $734 $182 
Fair value of liabilities assumed183 34 16 
Fair value of net assets acquired2,214 700 166 
Merger consideration payable— (88)(18)
Cash paid for business acquisitions2,214 612 148 
Less: Cash acquired50 1 4 
Business acquisitions, net of cash acquired$2,164 $611 $144 

202420232022
Leases:
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$201 $192 $185 
Operating cash flows from finance leases$1 $— $1 
Financing cash flows from finance leases$1 $1 $1 
Leased assets obtained in exchange for new operating lease liabilities$154 $181 $154 

    During the years ended December 31, 2024, 2023 and 2022, costs associated with donations, contributions, and other financial support through Quest for Health Equity, the Company's initiative with the Quest Diagnostics Foundation to reduce health disparities in underserved communities, were $0 million, $0 million and $93 million, respectively. Such amounts are included in selling, general and administrative expenses in the Company's consolidated statement of operations. Costs incurred during the year ended December 31, 2022 will be donated and contributed over several years.
    During the years ended December 31, 2024, 2023 and 2022, other financing activities, net in the Company's consolidated statement of cash flows included changes in bank overdrafts, which are generally settled in cash in the short term, of $33 million, $36 million and $(24) million, respectively.